New Age Metals (CVE:NAM) Stock Price Down 17.8% – Here’s Why
by Mitch Edgeman · The Markets DailyNew Age Metals Inc. (CVE:NAM – Get Free Report)’s stock price traded down 17.8% during mid-day trading on Saturday . The stock traded as low as C$0.37 and last traded at C$0.37. 719,175 shares were traded during mid-day trading, an increase of 581% from the average session volume of 105,542 shares. The stock had previously closed at C$0.45.
Analyst Ratings Changes
Separately, Fundamental Research set a C$0.95 price target on New Age Metals and gave the stock a “buy” rating in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, New Age Metals currently has a consensus rating of “Buy” and a consensus price target of C$0.95.
Check Out Our Latest Report on NAM
New Age Metals Price Performance
The company has a market capitalization of C$24.58 million, a P/E ratio of -61.67 and a beta of 0.08. The company’s 50-day moving average price is C$0.36 and its two-hundred day moving average price is C$0.29. The company has a debt-to-equity ratio of 0.74, a current ratio of 52.48 and a quick ratio of 17.88.
New Age Metals Company Profile
New Age Metals Inc, a mineral exploration company, engages in the acquisition, exploration, and development of platinum group metals (PGMs), and precious and base metal properties in Canada. The company explores for rhodium, palladium, platinum, gold, nickel, copper, and lithium deposits. It holds interests in the River Valley PGE project located in the Dana and Pardo townships of Northern Ontario; the Genesis PGE project located in south central Alaska; and lithium projects situated to the northeast of Winnipeg, Manitoba.
Read More
- Five stocks we like better than New Age Metals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why Amazon Could Be a $300 Stock Within Weeks
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 12/8 – 12/12